Cargando…

Anti-atherogenic and anti-ischemic potentials of Croton membranaceus observed during sub-chronic toxicity studies

BACKGROUND: Croton membranaceus (CM) is used for benign prostate hyperplasia treatment. OBJECTIVE: Sub-chronic toxicity studies are non-existent and provided the basis for this study. MATERIALS AND METHODS: 90 days oral administration of a low dose (LD) (30 mg/kg b. wt.), medium dose (MD) (150 mg/kg...

Descripción completa

Detalles Bibliográficos
Autores principales: Afriyie, Dan K., Asare, George A., Bugyei, Kwasi, Asiedu-Gyekye, Isaac, Gyan, Ben A., Adjei, Samuel, Addo, Phyllis, Sittie, Archibald, Nyarko, Alexander K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579014/
https://www.ncbi.nlm.nih.gov/pubmed/23598919
http://dx.doi.org/10.4103/0974-8490.105640
_version_ 1782260070090801152
author Afriyie, Dan K.
Asare, George A.
Bugyei, Kwasi
Asiedu-Gyekye, Isaac
Gyan, Ben A.
Adjei, Samuel
Addo, Phyllis
Sittie, Archibald
Nyarko, Alexander K.
author_facet Afriyie, Dan K.
Asare, George A.
Bugyei, Kwasi
Asiedu-Gyekye, Isaac
Gyan, Ben A.
Adjei, Samuel
Addo, Phyllis
Sittie, Archibald
Nyarko, Alexander K.
author_sort Afriyie, Dan K.
collection PubMed
description BACKGROUND: Croton membranaceus (CM) is used for benign prostate hyperplasia treatment. OBJECTIVE: Sub-chronic toxicity studies are non-existent and provided the basis for this study. MATERIALS AND METHODS: 90 days oral administration of a low dose (LD) (30 mg/kg b. wt.), medium dose (MD) (150 mg/kg b. wt.), and high dose (HD) (300 mg/kg b. wt.) CM aqueous root extract to 3 groups (n=6 each) of male Sprague-Dawley rats, alongside a control group, was undertaken. Urinalysis, hepato-renal function tests, lipid profile, cardiac enzymes, and routine hematology tests were performed. RESULTS: Triglyceride levels (C=1.05±0.19, LD=0.64±0.08, MD=0.55±0.04, HD=0.50±0.02 mmol/L) were significantly reduced (P<0.05). Very low density lipoprotein (C=0.48±0.09, LD=0.29±0.04, MD=0.25±0.02, HD=0.23±0.01 mmol/L) decreased significantly (P<0.05). Cardiac enzymes-creatinine kinase (C=568±172, LD=315±79, MD=441±209, HD=286±81 IU/L) decreased markedly (P<0.05) alongside lactate dehydrogenase (C=2675±875, LD=1667±1229, MD=1186±442, HD=855±239 IU/L) (P<0.05). CONCLUSION: C. membranaceus aqueous root extract is non-toxic but demonstrates anti-atherogenic and anti-ischemic potentials.
format Online
Article
Text
id pubmed-3579014
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-35790142013-02-28 Anti-atherogenic and anti-ischemic potentials of Croton membranaceus observed during sub-chronic toxicity studies Afriyie, Dan K. Asare, George A. Bugyei, Kwasi Asiedu-Gyekye, Isaac Gyan, Ben A. Adjei, Samuel Addo, Phyllis Sittie, Archibald Nyarko, Alexander K. Pharmacognosy Res Original Article BACKGROUND: Croton membranaceus (CM) is used for benign prostate hyperplasia treatment. OBJECTIVE: Sub-chronic toxicity studies are non-existent and provided the basis for this study. MATERIALS AND METHODS: 90 days oral administration of a low dose (LD) (30 mg/kg b. wt.), medium dose (MD) (150 mg/kg b. wt.), and high dose (HD) (300 mg/kg b. wt.) CM aqueous root extract to 3 groups (n=6 each) of male Sprague-Dawley rats, alongside a control group, was undertaken. Urinalysis, hepato-renal function tests, lipid profile, cardiac enzymes, and routine hematology tests were performed. RESULTS: Triglyceride levels (C=1.05±0.19, LD=0.64±0.08, MD=0.55±0.04, HD=0.50±0.02 mmol/L) were significantly reduced (P<0.05). Very low density lipoprotein (C=0.48±0.09, LD=0.29±0.04, MD=0.25±0.02, HD=0.23±0.01 mmol/L) decreased significantly (P<0.05). Cardiac enzymes-creatinine kinase (C=568±172, LD=315±79, MD=441±209, HD=286±81 IU/L) decreased markedly (P<0.05) alongside lactate dehydrogenase (C=2675±875, LD=1667±1229, MD=1186±442, HD=855±239 IU/L) (P<0.05). CONCLUSION: C. membranaceus aqueous root extract is non-toxic but demonstrates anti-atherogenic and anti-ischemic potentials. Medknow Publications & Media Pvt Ltd 2013 /pmc/articles/PMC3579014/ /pubmed/23598919 http://dx.doi.org/10.4103/0974-8490.105640 Text en Copyright: © Pharmacognosy Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Afriyie, Dan K.
Asare, George A.
Bugyei, Kwasi
Asiedu-Gyekye, Isaac
Gyan, Ben A.
Adjei, Samuel
Addo, Phyllis
Sittie, Archibald
Nyarko, Alexander K.
Anti-atherogenic and anti-ischemic potentials of Croton membranaceus observed during sub-chronic toxicity studies
title Anti-atherogenic and anti-ischemic potentials of Croton membranaceus observed during sub-chronic toxicity studies
title_full Anti-atherogenic and anti-ischemic potentials of Croton membranaceus observed during sub-chronic toxicity studies
title_fullStr Anti-atherogenic and anti-ischemic potentials of Croton membranaceus observed during sub-chronic toxicity studies
title_full_unstemmed Anti-atherogenic and anti-ischemic potentials of Croton membranaceus observed during sub-chronic toxicity studies
title_short Anti-atherogenic and anti-ischemic potentials of Croton membranaceus observed during sub-chronic toxicity studies
title_sort anti-atherogenic and anti-ischemic potentials of croton membranaceus observed during sub-chronic toxicity studies
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579014/
https://www.ncbi.nlm.nih.gov/pubmed/23598919
http://dx.doi.org/10.4103/0974-8490.105640
work_keys_str_mv AT afriyiedank antiatherogenicandantiischemicpotentialsofcrotonmembranaceusobservedduringsubchronictoxicitystudies
AT asaregeorgea antiatherogenicandantiischemicpotentialsofcrotonmembranaceusobservedduringsubchronictoxicitystudies
AT bugyeikwasi antiatherogenicandantiischemicpotentialsofcrotonmembranaceusobservedduringsubchronictoxicitystudies
AT asiedugyekyeisaac antiatherogenicandantiischemicpotentialsofcrotonmembranaceusobservedduringsubchronictoxicitystudies
AT gyanbena antiatherogenicandantiischemicpotentialsofcrotonmembranaceusobservedduringsubchronictoxicitystudies
AT adjeisamuel antiatherogenicandantiischemicpotentialsofcrotonmembranaceusobservedduringsubchronictoxicitystudies
AT addophyllis antiatherogenicandantiischemicpotentialsofcrotonmembranaceusobservedduringsubchronictoxicitystudies
AT sittiearchibald antiatherogenicandantiischemicpotentialsofcrotonmembranaceusobservedduringsubchronictoxicitystudies
AT nyarkoalexanderk antiatherogenicandantiischemicpotentialsofcrotonmembranaceusobservedduringsubchronictoxicitystudies